ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail. 2013;1(6):500-7. 277. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiacresynchronizationtherapy inheart failurepatientswithandwithout previous rightventricular pacing. Eur J Heart Fail. 2014;16(11):1199-205. 278. Tayal B, Gorcsan J 3 rd , Delgado-Montero A, Goda A, Ryo K, Saba S, et al. Comparative long-termoutcomes after cardiac resynchronization therapy in right ventricular paced patients versus native wide left bundle branch block patients. Heart Rhythm. 2016;13(2):511-8. 279. Stankovic I, Prinz C, Ciarka A, Daraban AM, Mo Y, Aarones M, et al. Long- term outcome after CRT in the presence of mechanical dyssynchrony seen with chronic RV pacing or intrinsic LBBB. JACCCardiovasc Imaging. 2017;10(10 Pt A):1091-9. 280. Narang R, Cleland JG, Erhardt I, Ball SG, Coats AJ, Cowley AJ, et al. Mode of death in chronic heart failure. A request and propostion for more accurate classification. Eur Heart J. 1996;17(9):1390-403. 281. AdamsonPB,GilbertEM.Reducingtheriskofsuddendeath inheart failure with beta-blokers. J Card Fail. 2006;12(9):174-46. 282. Arshad A, Mandava A, Kamat G, Musat D. Sudden cardiac death: the role of medical therapy. Prog Cardiovasc Dis. 2008;50(6):420-38. 283. Shen L, Jhund OS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining risk of sudden cardiac death in heart failure. N Engl J Med. 2017;377(1):41-51. 284. Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Circulation. 2005;111(19):2537-49. 285. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Eng J Med. 1997;337(22):1576-83. 286. Connoly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071-8. 287. Moss AJ, Zareba W, Hall JW, Klein H, Wilber DJ, Cannom DS, et al. Multicenter Automatic Defibrillator Trial II invesgator (MADIT II). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. 288. Bardy GH, Lee KI, MarkDB, Poole JE, Packer DL, Boineau R, et al; Sudden CardiacDeath inHeart Failure Trial Investigators (SCDHeFT). Amiodarone or an implantable cardioverter-defibrilator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. 289. NisamS, Breithardt G. Lessons learned fromneutral ICD trials. Europace. 2006;8(6):393-97. 290. Kadish A, Dyler A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylatic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-8. 291. KoberL,Thune JJ,Nielsen JC,Haarbo J,VidebaekL,KorupE,etal.DANISH investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-30. 292. Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LY, Mark DB, Lee KL, et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomayopathy: a meta-analysis. JAMA Cardiol. 2017;2(6):685-8. 293. Stavrakis S, Asad Z, Reynolds D. Implantable cardioverter- defibrillators for primary prevention of mortality in patients with nonischemic cardiomayopathy: a meta-analysis of randomized controlled trials. J Cardiovasc Electrophysiol. 2017;28(6):659-65. 294. Shun-Shin MJ, Zheng LS, Cole GD, Howard JP, Whinnett ZI, Francis DP. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in 11 trials. Eur Heart J. 2017;38(22):1738-46. 295. Barakat AF, SaadM, Elgendy AM, Mentias A, Abuzaid A, Mahmoud AN, et al. Primary prevention implantable cardioverter defibrillators in patients with noischemic cardiomayopathy: a meta-analysis of randomised cotrolled trials. BMJ Open. 2017(6):e016352. 296. Kolodziejczak M, Andreotti F, Kowalewski M, Buffon A, Ciccone MM, Parati G, et al. Implantable cardioverter- defibrillators for primary prevention in patients with ischemic and nonischemic cardiomayopathy: a systematic review and meta-analysis. Ann Intern Med. 2017;167(2):103-11. 297. Pimentel M, Zimerman A, ChemelloD, Giaretta V, AndradesM, SilvelloD, et al. Predictors of serious arrhythmic events in patients with nonischemic heart failure. J Interv Card Electrophysiol. 2017;48(2):131-9. 298. Kirchof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. 299. Swdberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, KomajdaM, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers:results from COMET. Eur Heart J. 2005;26(13):1303-8. 300. Calvo N, Bisbal F, Guiu E, Ramos P, Nadal M, Tolosana JM, et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. Int J Cardiol. 2013;168(4):4093-7. 301. VanGelder IC,WyseDG,ChamdlerML,CooperHA,OlshanskyB,Hagens VE, et al. RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006; 8(11):935-942. 302. VanGelder IC, GroenveldHF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Eng J Med. 2010;362(15):1363-73. 303. Mareev Y, Cleland JG. Should beta-blockers be used in patients with heart failure and atrial fibrillation? ClinTher. 2015;37(10):2215-24. 304. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation: anindividual-patientdatameta-analysis.Lancet.2014;384(9961):2235-43. 305. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-77. 306. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion andmaintenance of sinusrhythmby amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98(23):2574-9. 307. Brodsky MA, Allen BJ, Walker CJ 3 rd , Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillationinthesettingofadilatedleftatrium.AmJCardiol.1987;60(7):572-5. 308. Ganesan AN, Nandal S, Lüker J, Pathak RK, Mahajan R, Twomey D, et al. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. Heart Lung Circ. 2015;24(3):270-80. 309. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-27. 310. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the EuroHeart Survey in atrial fibrillation. Chest. 2010;137(2):263-72. 525